Investor Overview

Investor Overview

Iovance Biotherapeutics aims to be the global leader in innovating, developing and delivering tumor infiltrating lymphocyte (TIL) therapies for patients with cancer. We are pioneering a transformational approach to cure cancer by harnessing the human immune system’s ability to recognize and destroy diverse cancer cells in each patient. Our lead late-stage TIL product candidate, lifileucel for metastatic melanoma, has the potential to become the first approved one-time cell therapy for a solid tumor cancer. The Iovance TIL platform has demonstrated promising clinical data across multiple solid tumors. We are committed to continuous innovation in cell therapy, including gene-edited cell therapy, that may extend and improve life for patients with cancer.

Latest Events
June 15, 2022 6:20 PM EDT
June 15, 2022 2:30 PM EDT
June 10, 2022 11:00 AM EDT
June 09, 2022 4:30 PM EDT
May 26, 2022 5:00 PM EDT

Stock Information

Data Provided by Refinitiv. Minimum 15 minutes delayed.